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Abstract 
Introduction: The effects on human health 
caused by the severe acute respiratory syndrome of 
coronavirus 2 (SARS-CoV-2) lead to hyperinflammation 
processes, which can lead to meta-inflammation. This 
process can aggravate skin diseases, especially 
psoriasis. This is a chronic inflammatory skin disease 
associated with significant morbidity. This problem 
affects about 2-3% of people worldwide. Objective: to 
demonstrate, through a concise systematic review, the 
main considerations about the relationship between 
COVID-19 and psoriasis, showing the possible 
mechanisms for the worsening of this dermatological 
disease. Methods: The research was carried out from 
June 2021 to July 2021 and developed based on Scopus, 
PubMed, Science Direct, Scielo, and Google Scholar, 
following the Systematic Review-PRISMA rules. The 
quality of the studies was based on the GRADE 
instrument and the risk of bias was analyzed according 
to the Cochrane instrument. Results: Psoriasis is a 
common chronic inflammatory skin disease and is 
autoimmune. Patients with COVID-19 may have 
features of hyper inflammation and even meta-
inflammation. The triggering or exacerbating factor of 
psoriasis may be medications and, in addition, patients 
with COVID-19 may have psoriasis exacerbation. 
Reports indicated that psoriasis patients using biological 
products were no longer susceptible to COVID-19 and 
the severe clinical course of the disease. It is envisioned 
that the use of azithromycin in cases of COVID 19 with 
pre-existing psoriasis can alleviate psoriatic lesions. 
Conclusion: The COVID 19 pandemic had a direct impact 
on dermatological diseases, especially psoriasis. Difficulty 
in accessing health care services and the stress load 
caused exacerbations in psoriasis cases. Studies 
recommend avoiding classic immunosuppressive agents 
such as methotrexate, cyclosporine, and TNF alpha 
inhibitors. Reports indicated that psoriasis patients using 
biological products were no longer susceptible to COVID-
19 and the severe clinical course of the disease. 
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In the COVID-19 pandemic scenario, the effects 
on human health caused by the severe acute respiratory 
syndrome of coronavirus 2 (SARS-CoV-2) lead to 
hyperinflammation processes, which can lead to meta-
inflammation [1]. This process can aggravate 
dermatological diseases, especially psoriasis [2,3]. This is 
a chronic inflammatory skin disease associated with 
significant morbidity [4]. This problem affects about 2-3% 
of people worldwide [5,6]. 
In this regard, COVID-19 is a highly contagious 
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pandemic has affected the treatment of psoriasis and an 
increasing number of studies in the current literature 
have focused on the relationship between psoriasis and 
COVID-19 from different perspectives. In this sense, 
conventional immunosuppressive therapies, such as 
methotrexate and cyclosporine, and anti-tumor necrosis 
factor agents should not be preferred due to the 
increased risk of infection, especially in high-risk areas. 
The use of cyclosporine may pose additional risk due to 
the side effect of hypertension. The treatment approach 
must be personalized, considering the advantages and 
disadvantages of each case separately [7,8]. 
In this context, primary and appendage 
mucocutaneous presentations can be the initial or 
evolutionary signs of COVID-19. It may most commonly 
present as an exanthatic or morbilliform maculopapular 
eruption, generalized urticaria, or pseudoflowering 
(pernio-like acral lesions or vasculopathy eruptions). 
Studies show that patients with active COVID-19 
infection should maintain biological 
immunosuppressants or not until complete recovery 
occurs, in at least 4 weeks [9]. 
Also, the COVID 19 pandemic changed the 
approach for all patients who need close contact during 
a dermatological consultation. The world's health 
systems were overwhelmed, and many centers were 
unable to serve a large number of patients. Thus, 
patients with psoriasis had only limited access to 
necessary health care [10,11]. 
Therefore, the present study aimed to highlight, 
through a concise systematic review, the main 
considerations about the relationship between COVID-
19 and psoriasis, showing the possible mechanisms for 




The rules of the Systematic Review-PRISMA 
Platform (Transparent reporting of systematic reviews 
and meta-analysis-HTTP://www.prisma-
statement.org/) were followed [12]. 
 
Data sources and research strategy 
The search strategies for this systematic review 
were based on the keywords (MeSH Terms): “COVID-
19. SARS-CoV-2. Psoriasis. Dermatological diseases. 
Hyperinflammation. Meta-inflammation”. The research 
was carried out from June 2021 to July 2021 and 
developed based on Scopus, PubMed, Science Direct, 
Scielo, and Google Scholar. Also, a combination of the 
keywords with the booleans "OR", “AND”, and the 
operator "NOT" were used to target the scientific articles 
of interest. 
 
Study Quality and Bias Risk 
The quality of the studies was based on the 
GRADE instrument [13] and the risk of bias was analyzed 
according to the Cochrane instrument [14]. Two 
independent reviewers carried out research and study 
selection. Data extraction was performed by reviewer 1 
and fully reviewed by reviewer 2. A third investigator 
decided on some conflicting points and made the final 
decision to choose the articles. 
 
Results and Development 
After the selectivity of articles and literary findings 
through the following descriptors COVID-19, SARS-CoV-2, 
Psoriasis, Dermatological diseases, Hyperinflammation, 
Meta-inflammation, a total of 312 studies were analyzed, 
with only 23 medium and high-quality studies selected, 
according to the rules of the GRADE, and with bias risks 
that do not compromise scientific development, based on 
the Cochrane instrument (Figure 1). 
After a complete analysis of the selected articles, 
it was found that psoriasis is a common chronic 
inflammatory skin disease, being autoimmune. A review 
study examined the overall infection risks of non-biological 
and biological systemic drugs for psoriasis. Thus, in 
patients with active infection, conventional systemic drugs 
such as tofacitinib and biological products for psoriasis 
should be temporarily discontinued. In uninfected 
patients, switching to safer alternatives should be 
considered. Interleukin (IL)-17, IL-12/23, and IL-23 
inhibitors are associated with a low risk of infection, with 
IL-17 and IL-23 favored over IL-12/23 inhibitors. 
Furthermore, studies suggest that IL-17 and IL-23 
blockers are safer than tumor necrosis factor alpha-
blockers. The drugs apremilast, acitretin, and dupilumab 
have favorable safety data and can be safely started and 
continued in uninfected patients [15]. 
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In this context, it is known that psoriasis is an 
immune-mediated genetic disease. Patients with COVID-
19 may have features of hyper inflammation and even 
meta-inflammation. The triggering or exacerbating factor 
of psoriasis can be medications and, in addition, patients 
with COVID-19 may have psoriasis exacerbation [16]. 
Therefore, there is concern about the 
susceptibility of patients with psoriasis to the use of 
biological products in the presence of COVID-19. Another 
review study examined whether biological treatment of 
psoriasis increases the risk of SARS-CoV-2 infection and 
whether biological products affect the clinical course of 
COVID-19 in these patients. According to 8,769 medical 
reports, about 0.3% of patients with psoriasis had 
COVID-19 and the hospitalization rate was 0.1%. No 
deaths due to COVID-19 were reported among 10509 
patients. Reports indicated that psoriasis patients using 
biological products were no longer susceptible to COVID-
19 and the severe clinical course of the disease [17]. 
In addition, one study found that the association 
of restriction of outdoor activities and loss of income with 
patient-reported outcomes of psoriasis during the 
COVID-19 pandemic, approximately 43.7% of 926 
patients described moderate to very marked worsening 
of psoriasis. Furthermore, the limitation of outdoor 
activity was found to be positively correlated with the 
worsening of psoriasis, stress and anxiety, and 
depression [18]. 
Therefore, the impact of COVID 19 on the course 
of psoriasis promotes hyperinflammation. Inflammation 
biomarkers such as C-reactive protein and ferritin were 
found to be significantly elevated in patients with Covid-
19 [19]. In their series of 52 patients, Kutlu and Metin 
found that 9.6% of patients with COVID-19 who were 
previously admitted to a dermatology clinic had psoriasis. 
This points out that patients with psoriasis may be more 
vulnerable to COVID 19 [20]. Furthermore, Ozaras et al 
reported a case of psoriasis possibly aggravated by 
COVID 19 [21]. In this context, it has been shown that 
psoriasis can be aggravated by the use of 
hydroxychloroquine. As evidence, the authors Kutlu and 
Metin reported a 71-year-old patient with COVID-19 who  
 
had a worsening of psoriasis after using 
hydroxychloroquine and oseltamivir [22]. 
In this sense, it is understood that 
hydroxychloroquine can increase the production of IL-
17, resulting in increased growth of keratinocytes [23]. 
Furthermore, Sachdeva et al identified 18 cases of 
psoriasis affected by hydroxychloroquine. Of the 18 
cases, 50.0% had new-onset psoriasis, 27.8% 
experienced a worsening of psoriatic lesions, and 22.2% 
had relapsed psoriasis. Despite this, a single-blind 
randomized controlled trial showed that azithromycin 
may be a potential therapeutic option for chronic plaque 
psoriasis through its immunomodulatory effect on 
epidermal Langerhans cells and keratinocytes [24]. 
Thus, it is seen that the use of azithromycin in cases of 
COVID 19 with pre-existing psoriasis can alleviate 
psoriatic lesions. 
In this setting, a study updated guidelines on the 
management of psoriatic disease during the COVID-19 
pandemic. The Task Force (TF) updated the evidence for 
the 22 original statements and added 5 new 
recommendations. The statements guide the treatment 
of patients with the psoriatic disease on topics including 
how the disease and its treatments affect the risk of 
COVID-19, how medical care can be optimized during the 
pandemic, what patients should do to decrease the risk 
of infection with COVID-19, including re-vaccination, and 
what they should do if they contract COVID-19 [25]. 
Furthermore, one study characterized the 
evolution of COVID-19 in patients with psoriasis. Of 374 
physician-reported patients in 25 countries, 71% were 
receiving a biologic, 18% were receiving a non-
biological, and 10% were not receiving any systemic 
psoriasis treatment. In all, 348 patients (93%) fully 
recovered from COVID-19, 77 (21%) were hospitalized 
and 9 (2%) died. The increased risk of hospitalization 
was associated with age, male gender, non-white 
ethnicity, and comorbid chronic lung disease. Still, 
hospitalization was more frequent in patients using non-




The COVID 19 pandemic directly impacted 
dermatological diseases, in particular psoriasis. Difficulty 
in accessing health care services and the stress load 
caused exacerbations in psoriasis cases. Studies 
recommend avoiding classic immunosuppressive agents 
such as methotrexate, cyclosporine, and TNF alpha 
inhibitors. Reports indicated that psoriasis patients using 
biological products were no longer susceptible to COVID-
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